
Chi dovrebbe assumere il farmaco preventivo dell'HIV, PrEP?
Revisione paritaria di Dr Krishna Vakharia, MRCGPAuthored by Lydia SmithPubblicato originariamente 13 Jan 2023
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Versione audio
- Add to preferred sources on Google
La profilassi pre-esposizione (PrEP) è un farmaco per prevenire lo sviluppo dell'HIV. È destinata alle persone che non sono affette da HIV, ma che hanno un'alta probabilità di sviluppare la condizione. Ma cos'è, come funziona e chi dovrebbe averne accesso?
In questo articolo:
Video picks for HIV e AIDS
Continua a leggere sotto
What is PrEP and how does it prevent HIV?
PrEP is a medication that prevents test HIV transmission. When taken as prescribed - usually a pill taken daily - it’s almost 100% effective. It works by helping the body to produce antibodies which prevent test HIV from replicating inside the body. Essentially, the drug stops the virus from crossing into the healthy cells and reproducing.
While it's possible to take so-called 'events-based PrEP' - when you take it as and when needed - daily dosing is generally considered more reliable.
Different PrEP delivery methods such as injectables and implants are also being researched. In 2021, the World Health Organisation recommended a new option called the anello vaginale for women at substantial risk of HIV acquisition1.
Who should take PrEP?
Torna ai contenutiAdam Freedman, senior policy and campaigns officer at the National AIDS Trust, says anyone who feels at risk of getting test HIV could consider taking PrEP. It may be suitable for you if you are test HIV negative or have sex in a variety of situations where preservativi are not easily or always used.
"That said, there are higher rates of HIV among certain demographics, including gay and bisexual and other men who have sex with men, migrants, Black Africans, Black Caribbeans, and transgender people," he says. "Uptake of PrEP has been higher among white gay and bisexual men, which has led to a corresponding drop in new diagnoses," Freedman adds.
"However, uptake has been much lower among other groups. That’s why it’s so important to make PrEP more accessible for everyone who needs it."
Evidence from the UK PROUD study reported that PrEP reduced the risk of HIV infection by 86% for men who have sex with men2. In 2021, however, NICE recommended promoting PrEP to several higher-risk groups, including test HIV negative men who have condomless sesso with other men and HIV-negative heterosexual men and women having condomless sex with partners who are test HIV positive. It also suggested promoting PrEP among HIV-negative trans women at elevated risk of developing test HIV through condomless sex3.
Continua a leggere sotto
How to access PrEP
Torna ai contenutiPrEP is available for free from sexual health clinics in England, Scotland, Wales and Northern Ireland.
"PrEP is available on the NHS, meaning everyone has the right to access it. If you want to start taking it, your first port of call should be your local sexual health clinic," says Freedman. "Lots of people choose to buy PrEP on the internet, which, while legal and typically safe, can be expensive. As we see it, no one should be forced to pay over-the-odds for a treatment which they’re legally entitled to receive from the NHS."
Why are people having problems accessing PrEP?
Torna ai contenutiThe UK Government pledged to end new cases of HIV infection by 2030, by scaling up test HIV testing and increasing access to PrEP among at-risk communities. However, researchers have warned this ambition may be under threat because access to PrEP in England is far lower than it should be.
Of 1,120 people who tried to get an appointment to get PrEP between October 2021 and July 2022, around two-thirds (68%) encountered problems. More than one third (35%) waited 12 weeks to be seen, and 57% waited more than 12 weeks4. Long waiting times, lack of appointments, and a training shortfall are all part of the problem, made worse by the COVID-19 pandemic and funding cuts5.
If you need PrEP or would like more information about it, it’s important to go to your sexual health clinic without delay.
Continua a leggere sotto
Ulteriori letture
Torna ai contenuti2. UK Proud study: Examining the impact on gay men of Pre-exposure Prophylaxis.
3. NICE: NICE recommends offering PrEP to people at high risk of HIV for first time.
4. BMJ: HIV: Two in three people have trouble getting PrEP, finds survey.
Patient picks for HIV e AIDS

Salute sessuale
Lo stigma dell'HIV e le rappresentazioni nei media
40 anni dalla pandemia di HIV, i progressi medici nella prevenzione e nel trattamento dell'HIV sono straordinari e salvavita. Sfortunatamente, questi progressi non sono accompagnati da cambiamenti nell'atteggiamento, e lo stigma e la discriminazione nei confronti delle persone con HIV rimangono radicati nella nostra cultura. I media svolgono un ruolo centrale nel plasmare narrazioni pericolose, spesso rappresentando le persone con HIV come irresponsabili e non sane.
di Amberley Davis

Salute sessuale
Quanto è efficace la PEP per prevenire l'HIV?
Oggigiorno, sappiamo tutti che l'HIV non è una condanna a morte. Grazie alla medicina moderna, le persone con HIV possono vivere vite lunghe, sane e completamente normali - qualcosa che solo pochi decenni fa sarebbe stato considerato un miracolo. Detto questo, se pensi di essere stato esposto all'HIV, è comprensibile che tu sia preoccupato. Non farti prendere dal panico - se affronti la situazione tempestivamente, c'è un modo affidabile per ridurre il rischio: la profilassi post-esposizione (PEP).
di Abi Millar
Continua a leggere sotto
About the author

Lydia Smith
Scrittore di articoli
BA, MA, MSc
Lydia Smith è una giornalista pluripremiata e scrittrice di articoli che ha scritto ampiamente sulla salute delle donne e sulla salute mentale. Attualmente sta studiando per un MSc in psicologia.
About the reviewerView full bio

Dr Krishna Vakharia, MRCGP
Chief Medical Officer for Health, Optum UK
MBChB, MRCGP(2013), BMedSci (hons), DFSRH, DRCOG, PGDipDerm (Distn)
Dr Krishna Vakharia is an NHS GP. She is also a regular examiner for the postgraduate Diploma in Practical Dermatology at Cardiff University as well as being the Chief Medical Officer for health at Optum UK.
Storia dell'articolo
Le informazioni su questa pagina sono revisionate da clinici qualificati.
13 Jan 2023 | Pubblicato originariamente
Autore:
Lydia SmithRevisione paritaria di
Dr Krishna Vakharia, MRCGP

Chiedi, condividi, connettiti.
Esplora le discussioni, fai domande e condividi esperienze su centinaia di argomenti di salute.

Non ti senti bene?
Valuta i tuoi sintomi online gratuitamente
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
By subscribing you accept our Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.